新日恆力(600165.SH):德運新材已完成對恆力新材的全部4.9億元出資
格隆匯10月21日丨新日恆力(600165.SH)公佈,經公司第八屆董事會第四次會議、2019年度第五次臨時股東大會審議通過了《關於寧夏新日恆力鋼絲繩股份有限公司放棄控股子公司寧夏恆力生物新材料有限責任公司49%股權優先購買權》的議案。
寧夏恆力生物新材料有限責任公司(以下簡稱:恆力新材)於2019年10月21日收到德運新材料科技股份有限公司(以下簡稱:德運新材)支付的2億元實繳註冊資本金。
截止公告披露日,德運新材完成了對恆力新材的全部4.9億元出資,根據協議約定,恆力新材於2019年10月21日返還德運新材履約保證金2500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.